Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24603326 | 1.00 | ALDH1A1 (0.30) | ALDH1A1NOS3NOS1NOS2MAPT | |
| SCHEMBL3859581 | 1.00 | ALDH1A1 (0.30) | ALDH1A1NOS3NOS1NOS2MAPT | |
| SCHEMBL10442624 | 0.95 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL10442622 | 0.95 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL10442623 | 0.95 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL11858505 | 0.93 | ALDH1A1 (0.32) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL31547150 | 0.93 | ALDH1A1 (0.32) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL11868988 | 0.91 | CA1 (0.31) | ALDH1A1NOS3NOS1NOS2MAPT | |
| SCHEMBL2299371 | 0.91 | MAPT (0.32) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL11857778 | 0.91 | MAPT (0.32) | ALDH1A1MAPTMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1538215-B1 | PROCESSES FOR PRODUCING LACTONE | TAKASAGO PERFUMERY CO LTD (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-7592350-B2 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2009-09-22 | — | — | US | disclosed |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2007-12-20 | — | — | US | disclosed |
| EP-1490361-B1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORP (FI) | 2007-10-03 | — | — | EP | disclosed |
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | DIN BELLE DAVID | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | ALDH1A1 1315/4885NOS3 1816/4885NOS1 1228/4885 |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | ALDH1A1 1315/4885NOS3 1816/4885NOS1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.